What question did this study set out to answer?

To determine the frequency, timing, and baseline clinical predictors of symptomatic intracerebral hemorrhage following intra-arterial thrombolysis with recombinant pro-urokinase in acute ischemic stroke.

November 13, 2001Neurology

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke

View Full Paper

Ask AI

Bookmark

Authors

CKCarlos S. KaseBoston University AFA J FurlanWestern Michigan University LWLawrence R. WechslerHospital of the University of Pennsylvania

Discussion

Member takes

Overview

Randomized trial reveals increased brain hemorrhage and mortality after intra-arterial thrombolysis in acute ischemic stroke, indicating baseline hyperglycemia markedly raises risk.

Key Points

To determine the frequency, timing, and baseline clinical predictors of symptomatic intracerebral hemorrhage following intra-arterial thrombolysis with recombinant pro-urokinase in acute ischemic stroke.
Exploratory treatment-received analysis of a randomized controlled trial in patients (N=180) with middle cerebral artery occlusion within 6 hours of stroke onset.
Evaluated patients receiving intra-arterial recombinant pro-urokinase plus intravenous heparin (n=110) versus intravenous heparin alone (n=64).
Defined symptomatic intracerebral hemorrhage as centrally adjudicated bleeding with an NIH Stroke Scale score worsening of ≥4 points within 36 hours.
Symptomatic intracerebral hemorrhage occurred in 10.9% (12/110) of recombinant pro-urokinase patients compared to 3.1% (2/64) of heparin-only controls, with an 83% (10/12) post-hemorrhage mortality rate.
Hemorrhage symptoms appeared at a mean of 10.2 ± 7.4 hours after starting treatment.
Baseline blood glucose >200 mg/dL was associated with a 36% risk of symptomatic hemorrhage versus 9% in patients with ≤200 mg/dL (p = 0.022; RR 4.2; 95% CI, 1.04 to 11.7).

Cite This Study

Kase et al. (2001) studied this question.

synapsesocial.com/papers/6a7dd4670210b8d50ccda916 https://doi.org/10.1212/wnl.57.9.1603

View Full Paper

Ask AI

Bookmark

November 13, 2001Neurology

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke

View Full Paper

Ask AI

Bookmark

Authors

CKCarlos S. KaseBoston University AFA J FurlanWestern Michigan University LWLawrence R. WechslerHospital of the University of Pennsylvania

Discussion

Member takes

Overview

Randomized trial reveals increased brain hemorrhage and mortality after intra-arterial thrombolysis in acute ischemic stroke, indicating baseline hyperglycemia markedly raises risk.

Key Points

To determine the frequency, timing, and baseline clinical predictors of symptomatic intracerebral hemorrhage following intra-arterial thrombolysis with recombinant pro-urokinase in acute ischemic stroke.
Exploratory treatment-received analysis of a randomized controlled trial in patients (N=180) with middle cerebral artery occlusion within 6 hours of stroke onset.
Evaluated patients receiving intra-arterial recombinant pro-urokinase plus intravenous heparin (n=110) versus intravenous heparin alone (n=64).
Defined symptomatic intracerebral hemorrhage as centrally adjudicated bleeding with an NIH Stroke Scale score worsening of ≥4 points within 36 hours.
Symptomatic intracerebral hemorrhage occurred in 10.9% (12/110) of recombinant pro-urokinase patients compared to 3.1% (2/64) of heparin-only controls, with an 83% (10/12) post-hemorrhage mortality rate.
Hemorrhage symptoms appeared at a mean of 10.2 ± 7.4 hours after starting treatment.
Baseline blood glucose >200 mg/dL was associated with a 36% risk of symptomatic hemorrhage versus 9% in patients with ≤200 mg/dL (p = 0.022; RR 4.2; 95% CI, 1.04 to 11.7).

Cite This Study

Kase et al. (2001) studied this question.

synapsesocial.com/papers/6a7dd4670210b8d50ccda916 https://doi.org/10.1212/wnl.57.9.1603

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark